Novavax :
NVAX
NVAX
Stock Data
$7.75
$0.48 (6.60%)
Asset Type
N/A
Exchange
N/A
Currency
N/A
Country
N/A
Sector
N/A
Industry
N/A
Novavax Inc is a biotechnology firm focused on enhancing global health by creating vaccines for serious infectious diseases. It uses innovative technologies like recombinant protein, nanoparticle technology, and its unique Matrix-M adjuvant to boost immune responses. The company has developed a COVID-19 vaccine, marketed under various names, for adults and adolescents. Additionally, Novavax is working on vaccines for influenza and a combination of influenza and COVID-19, as well as a malaria vaccine. Founded in 1987, Novavax is based in Gaithersburg, Maryland.
All Novavax Articles
201 Articles